CA2219867A1 - Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique - Google Patents

Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique Download PDF

Info

Publication number
CA2219867A1
CA2219867A1 CA002219867A CA2219867A CA2219867A1 CA 2219867 A1 CA2219867 A1 CA 2219867A1 CA 002219867 A CA002219867 A CA 002219867A CA 2219867 A CA2219867 A CA 2219867A CA 2219867 A1 CA2219867 A1 CA 2219867A1
Authority
CA
Canada
Prior art keywords
cells
proteasome
lac
inhibitor
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002219867A
Other languages
English (en)
Inventor
Jiangping Wu
Xin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Centre de Recherche du Centre Hospitalier de lUniversite de Montreal
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002219867A priority Critical patent/CA2219867A1/fr
Priority to PCT/CA1998/001010 priority patent/WO1999022729A1/fr
Priority to EP98951135A priority patent/EP0967976A1/fr
Priority to CA002276013A priority patent/CA2276013A1/fr
Priority to AU97318/98A priority patent/AU770798B2/en
Priority to JP52505499A priority patent/JP2001508465A/ja
Publication of CA2219867A1 publication Critical patent/CA2219867A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
CA002219867A 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique Abandoned CA2219867A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002219867A CA2219867A1 (fr) 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
PCT/CA1998/001010 WO1999022729A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de proteasomes dans le traitement du cancer, de l'inflammation, de maladies autoimmunes, du rejet du greffon et du choc septique
EP98951135A EP0967976A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de proteasomes dans le traitement du cancer, de l'inflammation, de maladies autoimmunes, du rejet du greffon et du choc septique
CA002276013A CA2276013A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique
AU97318/98A AU770798B2 (en) 1997-10-31 1998-10-29 The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
JP52505499A JP2001508465A (ja) 1997-10-31 1998-10-29 ガン、炎症、自己免疫疾患、移植片拒絶反応および敗血症性ショックを処置するためのプロテアソーム阻害因子の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002219867A CA2219867A1 (fr) 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique

Publications (1)

Publication Number Publication Date
CA2219867A1 true CA2219867A1 (fr) 1999-04-30

Family

ID=4161712

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002219867A Abandoned CA2219867A1 (fr) 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique

Country Status (5)

Country Link
EP (1) EP0967976A1 (fr)
JP (1) JP2001508465A (fr)
AU (1) AU770798B2 (fr)
CA (1) CA2219867A1 (fr)
WO (1) WO1999022729A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69920940T2 (de) * 1998-10-20 2005-11-17 Millennium Pharmaceuticals, Inc., Cambridge Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
JP2011195590A (ja) * 1999-10-20 2011-10-06 Osteoscreen Inc 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
US6692927B2 (en) * 2000-03-03 2004-02-17 University Of South Florida Bax degradation involvement in tumor survival and progression
DK1326632T3 (da) 2000-10-12 2007-01-15 Viromics Gmbh Protease-inhibitorer til behandling af infektioner af hepatitisvirus
WO2002080907A1 (fr) * 2001-04-03 2002-10-17 Millennium Pharmaceuticals, Inc. Combinaison d'analogue de lactacystine et de medicament immunosuppresseur permettant la prolongation de la survie d'une allogreffe
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
DE60218153T2 (de) 2001-05-21 2007-06-28 Alcon Inc. Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
WO2003084551A1 (fr) 2002-04-05 2003-10-16 Viromics Gmbh Agent de traitement d'infections par flaviviridae
DE10217254A1 (de) 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1565193B1 (fr) 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions de traitement du cancer au moyen d'inhibiteur PS-341 de la proteasome
CN1823070A (zh) * 2003-06-20 2006-08-23 加利福尼亚大学董事会 盐孢菌酰胺及其使用方法
BRPI0411677A (pt) 2003-06-20 2006-08-29 Nereus Pharmaceuticals Inc métodos de uso de compostos heterocìclicos [3.2.0] e seus análogos
AU2005212311A1 (en) * 2004-02-06 2005-08-25 The University Of Chicago An anti-inflammatory, cytoprotective factor derivable from a probiotic organism
AU2006249323B2 (en) 2005-05-27 2012-08-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US20100240581A1 (en) * 2006-11-13 2010-09-23 The Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
EP2088205A1 (fr) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique
CN102089312A (zh) 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
JP2010004750A (ja) * 2008-06-24 2010-01-14 Institute For Rheumatic Diseases Co Ltd 自己免疫疾患による組織傷害の発症または発症可能性の診断方法、およびその利用
SG195655A1 (en) * 2008-11-13 2013-12-30 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102711729B (zh) 2009-08-21 2015-04-01 诺万公司 局部用凝胶
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
DE102010039631A1 (de) * 2010-08-22 2012-02-23 Ulrich Schubert Pharmazeutische Zusammensetzungen mit immunmodulatorischen Eigenschaften
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2681286B1 (fr) 2011-02-28 2018-08-15 Novan, Inc. Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés
WO2012164398A2 (fr) * 2011-06-01 2012-12-06 Netherlands Cancer Institute Modulation du système ubiquitine-protéasome (ups)
KR101757373B1 (ko) * 2015-07-24 2017-07-26 울산과학기술원 프로테아좀 억제제 스크리닝용 조성물 및 이를 이용한 프로테아좀 억제제 스크리닝 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507754A (ja) * 1993-02-10 1996-08-20 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ Ｍｈｃ−１拘束性抗原提示におけるａｔｐ−ユビキチン依存蛋白分解の役割およびそのインヒビター
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
US11135198B2 (en) 2016-03-28 2021-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer

Also Published As

Publication number Publication date
WO1999022729A1 (fr) 1999-05-14
EP0967976A1 (fr) 2000-01-05
AU770798B2 (en) 2004-03-04
AU9731898A (en) 1999-05-24
JP2001508465A (ja) 2001-06-26

Similar Documents

Publication Publication Date Title
AU770798B2 (en) The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20020049157A1 (en) Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
Wang et al. Role of proteasomes in T cell activation and proliferation
Jensen et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing
Mandic et al. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis
Stangl et al. Long‐term up‐regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathway
Luo et al. A PROTEASOME INHIBITOR EFFECTIVELY PREVENTS MOUSE HEART ALLOGRAFT REJECTION1
Pendergraft III et al. Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1 to induce endothelial cell apoptosis
US20090227521A1 (en) Use of compounds in the treatment of ischemia and neurodegeneration
Schliep et al. Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia
Liu et al. The role of neutrophil elastase in aortic valve calcification
US7786170B2 (en) Histone deacetylase inhibitor enhancement of trail-induced apoptosis
Wall et al. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
EP1545287B1 (fr) Composes vasoregulateurs et procedes concernant leur utilisation
CA2276013A1 (fr) Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique
Shav-Tal et al. Enhanced proteolysis of pre-mRNA splicing factors in myeloid cells
CA2372316A1 (fr) Utilisation d'inhibiteurs de proteasome pour le traitement du cancer, des inflammations, des maladies autoimmunes, des rejets de greffes, et du choc septique
Shi et al. Potential effects of PKC or protease inhibitors on acute pancreatitis-induced tissue injury in rats
US9155774B2 (en) Scaffold-kinase interaction blockades and uses thereof in treating cancer
US7232570B2 (en) ERAAP modulators regulate immune responses
US20110065643A1 (en) Clusterin Pharmaceuticals and Treatment Methods Using the Same
JP2005537292A (ja) 内皮機能障害の治療および／または低用量プロテアソーム阻害剤療法におけるプロテアソーム阻害剤の使用
Zhang Development of cyclophilin inhibitors for the treatment of pancreatitis
WO2012068344A2 (fr) Régulation de cathepsine l par la dendrine de son facteur de transcription
WO2018085229A2 (fr) Lignées cellulaires résistantes et méthodes de traitement du cancer au moyen d'une combinaison d'un inhibiteur de hdac6 et d'un inhibiteur de la voie btk

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20040126